Maze Therapeutics (MAZE) Invested Capital (2024 - 2026)

Maze Therapeutics' Invested Capital history runs 3 years deep, the most recent figure standing at $380.5 million for Q1 2026.

• In Q1 2026, Invested Capital rose 30.29% year-over-year to $380.5 million; the TTM figure through Mar 2026 stood at $380.5 million (up 30.29% YoY), while the FY2025 annual figure was $355.0 million, up 214.07% from the prior year.
• Invested Capital came in at $380.5 million for Q1 2026 at Maze Therapeutics, up from $355.0 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $380.5 million in Q1 2026 to a low of -$403.7 million in Q1 2024.
• A 3-year average of $45.3 million and a median of $262.2 million in 2025 frame the typical range for Invested Capital.
• Across the five-year window, Invested Capital jumped 233.35% in 2025 and jumped 30.29% in 2026, its largest moves.
• Maze Therapeutics' Invested Capital stood at -$311.2 million in 2024, then surged by 214.07% to $355.0 million in 2025, then gained by 7.2% to $380.5 million in 2026.
• According to Business Quant data, Invested Capital over the past three periods registered $380.5 million, $355.0 million, and $379.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison